INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 42h ago
HOUSE PTR2h ago
SEC 13F2h ago
ROBINHOOD CHAIN2h ago
SEC FORM 4/Option exerciseVerified data

Kuan Arthur reported CGON

Director, Chief Executive Officer · CG Oncology, Inc. · CG Oncology, Inc. — Employee Stock Option (Right to Buy)

Side
M
Value
—
Shares
102.9K
Price
—
Executed
Mar 4, 2026
Disclosed
Mar 6, 2026
Disclosure timeline2 days from execution to publication · legal deadline 2 business days
Mar 4 executedMar 6, 2026 disclosed

CGON · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
9/ 100 · ROUTINE
Methodology →
  • Transaction type0 / 20

    Option exercise — administrative, little informational value

  • Relative size+1 / 25

No reported dollar value · new position

  • Filing timing0 / 15

    Disclosed 2 business days after execution (deadline: 2)

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · CGON

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    20
    KA
    Kuan ArthurDirector, Chief Executive Officer
    CGONCG Oncology, Inc.
    Option exercise
    		M$111K
    64.6K sh
    		Mar 12, 2026Mar 13, 2026
    traded Mar 12, 2026
    		+1dSEC FORM 4

    Evidence

    12
    KA
    Kuan ArthurDirector, Chief Executive Officer
    CGONCG Oncology, Inc.
    Tax withholding
    		F$111K
    1,847 sh
    		Mar 12, 2026Mar 13, 2026
    traded Mar 12, 2026
    		+1dSEC FORM 4

    Evidence

    9
    KA
    Kuan ArthurDirector, Chief Executive Officer
    CGONCG Oncology, Inc.
    Option exercise
    		M—
    64.6K sh
    		Mar 12, 2026Mar 13, 2026
    traded Mar 12, 2026
    		+1dSEC FORM 4

    Evidence

    24
    KA
    Kuan ArthurDirector, Chief Executive Officer
    CGONCG Oncology, Inc.
    Option exercise
    		M$177K
    102.9K sh
    		Mar 4, 2026Mar 6, 2026
    traded Mar 4, 2026
    		+2dSEC FORM 4

    Evidence

    12
    KA
    Kuan ArthurDirector, Chief Executive Officer
    CGONCG Oncology, Inc.
    Tax withholding
    		F$177K
    2,871 sh
    		Mar 4, 2026Mar 6, 2026
    traded Mar 4, 2026
    		+2dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0002007101-26-000002
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Mar 4, 2026
    Published
    Mar 6, 2026
    Ingested by INSIDER
    Nov 5, 04:13 UTC
    Last re-read
    Nov 5, 04:13 UTC

    Extracted facts

    Filer
    Kuan Arthur
    Role
    Director, Chief Executive Officer
    Transaction
    Option exerciseAs filed: “M”
    Asset
    CG Oncology, Inc. — Employee Stock Option (Right to Buy)
    Ticker
    CGON
    Shares
    102.9K
    Price per share
    $0
    Execution date (reported)
    Mar 4, 2026
    Owned after transaction
    64.6K shares
    Days from execution to publication
    2

    What this establishes

    Kuan Arthur filed this Form 4 reporting a option exercise of CGON on Mar 4, 2026. It became public on Mar 6, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    Director, Chief Executive Officer
    Kuan Arthurcik:0002007101
    Issuer
    CG Oncology, Inc.cik:0001991792

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.